Monoclonal Antibody Therapeutics 2009-2024

Table of Contents

1 Executive Summary

2 Introduction to Monoclonal Antibodies

• 2.1 Antibodies
  • 2.1.1 Function of Antibodies
  • 2.1.2 Structure of Antibodies
• 2.2 Monoclonal Antibody Therapeutics
  • 2.2.1 Polyclonal and Monoclonal Antibodies
  • 2.2.2 Murine Monoclonal Antibodies
  • 2.2.3 Chimeric and Humanised Monoclonal Antibodies
  • 2.2.4 Fully-Human Monoclonal Antibodies
  • 2.2.5 Currently-Approved Monoclonal Antibody Therapeutics

3 The Global Monoclonal Antibodies Market, 2009-2024

• 3.1 Monoclonal Antibodies: Market Overview
  • 3.1.1 Size of Monoclonal Antibody Market in 2008
  • 3.1.2 Monoclonal Antibodies: Revenue Analysis by Therapeutic Area, 2008
  • 3.1.3 Leading Monoclonal Antibodies: Revenue Analysis, 2008
  • 3.1.4 Monoclonal Antibodies: Revenue Analysis by Type, 2008
  • 3.1.5 Monoclonal Antibodies: Revenue Analysis by Company, 2008
  • 3.1.6 Global Monoclonal Antibody Market Forecast, 2009-2014
  • 3.1.7 Monoclonal Antibodies Sales Forecast, 2014-2024
• 3.2 The Oncology Monoclonal Antibodies Market
  • 3.2.1 Leading Oncology Monoclonal Antibodies: Revenue Analysis, 2008
  • 3.2.2 Oncology Monoclonal Antibodies: Revenue Analysis by Type, 2008
  • 3.2.3 Oncology Monoclonal Antibodies: Revenue Analysis by Company, 2008
  • 3.2.4 Continuing High Growth: Oncology Monoclonal Antibodies, 2009-2014
  • 3.2.5 Oncology Monoclonal Antibodies Sales Forecast, 2014-2024
• 3.3 MabThera/Rituxan
  • 3.3.1 MabThera/Rituxan: The First Blockbuster Monoclonal Antibody
  • 3.3.2 MabThera/Rituxan Revenue Analysis, 2008
  • 3.3.3 MabThera/Rituxan Market Forecast, 2009-2014
  • 3.3.4 MabThera/Rituxan Long-Term Prospects, 2014-2024
  • 3.3.5 New Oncology Growth Areas for MabThera/Rituxan, 2009-2014
  • 3.3.6 Intensifying Competition: MabThera/Rituxan in Oncology, 2014-2024
• 3.4 Avastin
  • 3.4.1 Avastin: A Cancer Blockbuster Set To Reach $10bn
  • 3.4.2 Avastin Revenue Analysis, 2008
  • 3.4.3 Avastin 2009-2014: ' a Pipeline-In-One'
  • 3.4.4 The Competitive Landscape for Avastin, 2009-2014
  • 3.4.5 Avastin Market Forecast, 2009-2014
  • 3.4.6 Outlook for Avastin: Sales Forecast, 2014-2024
• 3.5 Herceptin
  • 3.5.1 Herceptin Successfully Targets HER2-Positive Patients
  • 3.5.2 Herceptin Revenue Analysis, 2008
  • 3.5.3 Herceptin Market Forecast, 2009-2014
  • 3.5.4 Increased Competition for Herceptin, 2014-2024
• 3.6 Erbitux
  • 3.6.1 Erbitux' s Oncology Indications
  • 3.6.2 Erbitux Revenue Analysis, 2008
  • 3.6.3 Opportunity in Head and Neck Cancer and New Indications for Erbitux
  • 3.6.4 Erbitux Sales Forecast, 2009-2024
• 3.7 Other Oncology Monoclonal Antibodies
  • 3.7.1 Vectibix
  • 3.7.2 Vectibix Revenue Analysis, 2008
  • 3.7.3 Campath/MabCampath
  • 3.7.4 Campath/MabCampath Revenue Analysis
  • 3.7.5 Mylotarg
  • 3.7.6 Zevalin
  • 3.7.7 Bexxar
  • 3.7.8 TheraCIM (Nimotuzumab)
  • 3.7.9 Removab
• 3.8 The Autoimmune Disorder Monoclonal Antibodies Market
  • 3.8.1 Leading Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis, 2008
  • 3.8.2 Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis by Type, 2008
  • 3.8.3 Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis by Company, 2008
  • 3.8.4 Humira and Novel Antibodies Drive Autoimmune Monoclonal Market, 2009-2014
  • 3.8.5 Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2014-2024
• 3.9 Remicade
  • 3.9.1 Remicade: Leading Anti-TNF Drug
  • 3.9.2 Remicade Revenue Analysis, 2008
  • 3.9.3 Remicade' s Competitors
  • 3.9.4 Imminent Increase in Competition for Remicade
  • 3.9.5 Remicade Market Forecast, 2009-2014
  • 3.9.6 Remicade Market Forecast, 2015-2025
• 3.10 Humira
  • 3.10.1 Humira: First Fully-Human Monoclonal Antibody on Market
  • 3.10.2 Humira Revenue Analysis, 2008
  • 3.10.3 Humira' s Market Potential, 2009-2014
  • 3.10.4 Humira Sales Forecast, 2015-2024
• 3.11 Novel Anti-TNF Monoclonal Antibodies
  • 3.11.1 Cimzia: Newly-Approved Fully-Human Monoclonal Antibody
  • 3.11.2 Cimzia Sales Forecast, 2009-2024
  • 3.11.3 Simponi
  • 3.11.4 Simponi Sales Forecast, 2009-2024
• 3.12 MabThera/Rituxan for Autoimmune Disorders
  • 3.12.1 MabThera/Rituxan: Not Just for Oncology
  • 3.12.2 Raft of Competitors for MabThera/Rituxan in Autoimmune Disorders, 2009-2024
• 3.13 Xolair
  • 3.13.1 Genentech' s Asthma Monoclonal Antibody: Xolair
  • 3.13.2 Xolair Revenue Analysis, 2008
  • 3.13.3 Xolair Sales Forecast, 2009-2014
• 3.14 Tysabri
  • 3.14.1 Tysabri
  • 3.14.2 Tysabri Revenue Analysis, 2008
  • 3.14.3 Tysabri Sales Forecast, 2009-2024
• 3.15 Other Autoimmune Disorder Monoclonal Antibodies
  • 3.15.1 Soliris
  • 3.15.2 Soliris Revenue Analysis, 2008
  • 3.15.3 Raptiva
  • 3.15.4 Raptiva Revenue Analysis, 2008
  • 3.15.5 Raptiva Withdrawn from Market in 2009
  • 3.15.6 Simulect
  • 3.15.7 Actemra/RoActemra
  • 3.15.8 Zenapax
  • 3.15.9 Orthoclone OKT3
  • 3.15.10 Stelara
  • 3.15.11 Simponi
• 3.16 Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders)
  • 3.16.1 Other Leading Monoclonal Antibodies: Revenue Analysis, 2008
  • 3.16.2 Other Monoclonal Antibodies Sales Forecast, 2009-2024
• 3.17 Lucentis
  • 3.17.1 Lucentis: Serendipitous Antibody Fragment for Ophthalmology
  • 3.17.2 Lucentis Revenue Analysis, 2008
  • 3.17.3 Impact of Off-Label Avastin on Lucentis, 2009-2024
  • 3.17.4 Lucentis Sales Forecast, 2009-2014
  • 3.17.5 Lucentis Sales Forecast, 2014-2024
• 3.18 Synagis
  • 3.18.1 Synagis: Sole Blockbuster Respiratory Disorder Monoclonal Antibody
  • 3.18.2 Synagis Revenue Analysis, 2008
  • 3.18.3 Synagis/Motavizumab Market Forecast, 2009-2024
• 3.19 ReoPro
  • 3.19.1 ReoPro: Cardiovascular Monoclonal Antibody Fragment
  • 3.19.2 ReoPro Revenue Analysis, 2008

4 Monoclonal Antibody Country Markets

• 4.1 Regional Overview
  • 4.1.1 Top Eight Monoclonal Antibody Country Markets, 2008
  • 4.1.2 US, Canada, France, Germany, Spain, Italy, UK, Japan, China & India Monoclonal Antibody Market Forecasts, 2009-2024
• 4.2 The US Monoclonal Antibody Therapeutics Market
  • 4.2.1 US Market in 2008
  • 4.2.2 US Monoclonal Antibodies Sales Forecast, 2009-2024
• 4.3 European Monoclonal Antibody Therapeutics Market
• 4.4 Monoclonal Antibodies in Emerging Markets

5 The Monoclonal Antibody Therapeutic Pipeline

• 5.1 Late-Stage Oncology Pipeline: Additional and Expanded Indications
  • 5.1.1 Avastin
  • 5.1.2 MabThera/Rituxan
  • 5.1.3 Erbitux
  • 5.1.4 Tysabri
• 5.2 Late-Stage Oncology Pipeline: Novel Entities
  • 5.2.1 Arzerra (Ofatumumab)
  • 5.2.2 Farletuzumab (MORAb-003)
  • 5.2.3 Figitumumab (CP-751871)
  • 5.2.4 Galiximab
  • 5.2.5 Ipilimumab
  • 5.2.6 Ramucirumab (IMC 1121B)
  • 5.2.7 Rencarex (WX-G250)
  • 5.2.8 Zalutumumab (HuMax-EGFr)
  • 5.2.9 Lumiliximab
  • 5.2.10 Pertuzumab (R1273)
• 5.3 Late-Stage Autoimmune Disorder Pipeline: Additional and Expanded Indications
  • 5.3.1 Actemra/RoActemra
  • 5.3.2 MabThera/Rituximab
  • 5.3.3 Alemtuzumab for Multiple Sclerosis
• 5.4 Late-Stage Autoimmune Disorder Pipeline: New Entities
  • 5.4.1 Ilaris (Canakinumab)
  • 5.4.2 Stelara (Ustekinumab)
  • 5.4.3 Simponi (Golimumab)
  • 5.4.4 Bapineuzumab ((AAB-001)
  • 5.4.5 Benlysta (Belimumab)
  • 5.4.6 ABT-874
  • 5.4.7 Mycograb (Efungumab)
  • 5.4.8 Ocrelizumab (R1594)
  • 5.4.9 Otelixizumab (TRX4)
  • 5.4.10 Reslizumab (Reslizumab)
  • 5.4.11 Solanezumab
  • 5.4.12 Tanezumab (PF-4383119)
  • 5.4.13 Teplizumab (MGA031)
  • 5.4.14 Vedolizmab (MLN0002)
• 5.5 Other Monoclonal Antibodies Pipeline (Non-Oncology/Autoimmune Disorders)
  • 5.5.1 Denosumab: Promising Bone Disorder Pipeline Drug
  • 5.5.2 Denosumab: Competitor Analysis
  • 5.5.3 Motavizumab
  • 5.5.4 Bosatria (Mepolizumab)
  • 5.5.5 Lucentis
• 5.6 Early Stage Pipeline: Antibody Fragments
  • 5.6.1 Development and Potential of Antibody Fragments
  • 5.6.2 Ablynx' s Nanobodies: Future Cash Llama?
  • 5.6.3 Domantis' Domain Fragments
  • 5.6.4 Genmab' s UniBodies
  • 5.6.5 ESBATech
  • 5.6.6 Affimed' s TandAbs and Flexibodies
  • 5.6.7 Micromet' s BiTE Antibody Platform
• 5.7 Early Stage Pipeline: Antibody-Drug Conjugates
  • 5.7.1 The Future of Conjugated Antibodies
  • 5.7.2 Seattle Therapeutics
  • 5.7.3 ImmunoGen' s TAP Technology
  • 5.7.4 Neuradiab

6 Issues Affecting the Monoclonal Antibodies Market

• 6.1 SWOT Chart for the Monoclonal Antibodies Industry
• 6.2 Strengths
  • 6.2.1 Monoclonal Antibodies Have a Wide Range of Specific Targets
  • 6.2.2 Chronic and Niche Diseases Generate High Revenues
  • 6.2.3 Rich Pipeline and Manufacturing Improvements
  • 6.2.4 Lower Risk of Adverse Events for Oncology Monoclonal Antibodies
• 6.3 Weaknesses
  • 6.3.1 Biosimilar Monoclonal Antibodies
  • 6.3.2 Future Prospects for Biosimilar Monoclonal Antibodies
  • 6.3.3 High Development Cost Limits Growth
  • 6.3.4 Injections are the Main Mode of Administration
  • 6.3.5 The Challenge of Immunogenicity Still Looms Large
  • 6.3.6 Competition is Fierce for Many Targets
  • 6.3.7 Insufficient Efficacy of Oncology Monoclonal Antibodies as Monotherapy
• 6.4 Opportunities
  • 6.4.1 Increasing Cancer Prevalence
  • 6.4.2 Autoimmune Disorder Prevalence and Under-Treatment
• 6.5 Threats
  • 6.5.1 Lack of Reimbursement for Monoclonal Antibodies
  • 6.5.2 High Profile Safety Cases Increase Regulatory Concerns
  • 6.5.3 Current Financial Limitations in Research and Development

7 Interviews with Monoclonal Antibody Industry Key Opinion Leaders

• 7.1 Dr Debbie Law, Chief Scientific Officer, and Eva-Lotta Allan, Chief Business Office, Ablynx
  • 7.1.1 Future Prospects for Full-Size Monoclonal Antibodies, Conjugated Antibodies and Fragment Antibodies
  • 7.1.2 Nanobodies
  • 7.1.3 Immunogenicity of Nanobodies
  • 7.1.4 Ablynx' s Anti-Thrombotic Nanobody Pipeline
  • 7.1.5 Anti-TNF and Anti-RANKL Nanobodies
  • 7.1.6 Potential Advantages of Anti-Thrombotic Nanobodies
  • 7.1.7 Multi-Valency and Multi-Specificity: Nanobodies as Building Blocks
  • 7.1.8 New Delivery Methods
  • 7.1.9 Future Commercial Direction of Monoclonal Antibody and Antibody Fragments
• 7.2 Janice M. Reichert, PhD, Senior Research Fellow at Tufts University
  • 7.2.1 Major Challenges and Opportunities for Monoclonal Antibody Cancer Therapeutics
  • 7.2.2 Side-Effects of Monoclonal Antibodies for Cancer
  • 7.2.3 Future Developments and Pipelines
  • 7.2.4 The Effect of Biosimilars
• 7.3 David Blakey, PhD, Chief Scientist, Cancer & Infection Research Area, AstraZeneca
  • 7.3.1 The Future of Humanised and Fully-Human Antibodies
  • 7.3.2 Therapeutic Antibody Fragments Versus Full-Length Antibodies
  • 7.3.3 Major Opportunities in Monoclonal Antibody Cancer Therapeutics

8 Conclusions

• 8.1 Monoclonal Antibodies Account for Over 30% of Biologic Drug Revenues
• 8.2 Future Prospects for the Monoclonal Antibody Market
• 8.3 The Monoclonal Antibody Pipeline
• 8.4 Recent High Growth Rates Set to Continue to 2014
• 8.5 Market Forecast, 2014-2024
• 8.6 Expansion into New Markets
• 8.7 Future Outlook

List of Tables

• Table 2.1 Monoclonal Antibody Technology
• Table 2.2 Modes of Action for Monoclonal Antibody Therapeutics
• Table 2.3 Monoclonal Antibody Therapeutics Approved by US FDA, 1986-2003
• Table 2.4 Monoclonal Antibody Therapeutics Approved by US FDA, 2003-2009
• Table 3.1 Monoclonal Antibody Sales by Therapeutic Area, 2008
• Table 3.2 Sales of Leading Monoclonal Antibodies, 2008
• Table 3.3 Monoclonal Antibody Sales by Technology Type, 2008
• Table 3.4 Sales of Monoclonal Antibodies by Antibody Type, 2008
• Table 3.5 Sales of Monoclonal Antibodies by Marketing Company, 2008
• Table 3.6 Monoclonal Antibody Therapeutic Market, Drivers & Restraints, 2009-2024
• Table 3.7 Total, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2009-2014
• Table 3.8 Total, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2015-2024
• Table 3.9 Sales of Leading Oncology Monoclonal Antibodies, 2008
• Table 3.10 Sales by Technology Type, Oncology Monoclonal Antibodies, 2008
• Table 3.11 Sales by Antibody Type, Oncology Monoclonal Antibodies, 2008
• Table 3.12 Sales by Marketing Company, Oncology Monoclonal Antibodies, 2008
• Table 3.13 Oncology Monoclonal Antibodies, Drivers & Restraints, 2009-2024
• Table 3.14 MabThera/Rituxan, Avastin, Herceptin, Erbitux & Total Oncology Monoclonal Antibodies Sales Forecasts, 2009-2014
• Table 3.15 MabThera/Rituxan, Avastin, Herceptin, Erbitux & Total Oncology Monoclonal Antibodies Sales Forecasts, 2015-2024
• Table 3.16 MabThera/Rituxan Sales by Marketing Company, 2008
• Table 3.17 MabThera/Rituxan Sales by Country, 2008
• Table 3.18 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2009-2014
• Table 3.19 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2015-2024
• Table 3.20 MabThera/Rituxan, Drivers & Restraints, 2009-2024
• Table 3.21 Avastin Sales by Marketing Company, 2008
• Table 3.22 Avastin Sales by Country, 2008
• Table 3.23 Avastin, Drivers & Restraints, 2009-2024
• Table 3.24 Herceptin Sales by Marketing Company, 2008
• Table 3.25 Herceptin Sales by Country, 2008
• Table 3.26 Herceptin, Drivers & Restraints, 2009-2024
• Table 3.27 Erbitux Sales by Marketing Company, 2008
• Table 3.28 Erbitux Sales by Country, 2008
• Table 3.29 Erbitux, Drivers & Restraints, 2009-2024
• Table 3.30 Major Nimotuzumab Markets, 2009
• Table 3.31 Sales of Leading Autoimmune Disorder Monoclonal Antibodies, 2008
• Table 3.32 Sales by Technology Type, Autoimmune Disorder Monoclonal Antibodies, 2008
• Table 3.33 Sales by Antibody Type, Autoimmune Disorder Monoclonal Antibodies, 2008
• Table 3.34 Sales by Marketing Company, Autoimmune Disorder Monoclonal Antibodies, 2008
• Table 3.35 Autoimmune Disorder Monoclonal Antibodies, Drivers & Restraints, 2009-2024
• Table 3.36 Remicade, Humira, Simponi, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2009-2014
• Table 3.37 Remicade, Humira, Simponi, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2015-2024
• Table 3.38 Remicade Sales by Marketing Company, 2008
• Table 3.39 Remicade Sales by Country, 2008
• Table 3.40 Remicade, Drivers & Restraints, 2009-2024
• Table 3.41 Approved Indications for Humira in the US
• Table 3.42 Humira Sales by Marketing Company, 2008
• Table 3.43 Humira Sales by Country, 2008
• Table 3.44 Humira, Drivers & Restraints, 2009-2024
• Table 3.45 Cimzia, Drivers & Restraints, 2009-2024
• Table 3.46 Simponi, Drivers & Restraints, 2009-2024
• Table 3.47 MabThera/Rituxan (Autoimmune Indications), Xolair & Tysabri Sales Forecasts, 2009-2014
• Table 3.48 MabThera/Rituxan (Autoimmune Indications), Xolair, & Tysabri Sales Forecasts, 2015-2024
• Table 3.49 Tysabri Sales by Country, 2008
• Table 3.50 Sales of Leading Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders), 2008
• Table 3.51 Lucentis, Synagis/Motavizumab and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2009-2014
• Table 3.52 Lucentis, Synagis/Motavizumab and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2015-2024
• Table 3.53 Lucentis Sales by Marketing Company, 2008
• Table 3.54 Lucentis Sales by Country, 2008
• Table 3.55 Drivers and Restraints on Lucentis Revenues, 2009-2014
• Table 3.56 Synagis Sales by Marketing Company, 2008
• Table 3.57 Synagis Sales by Country, 2008
• Table 4.1 Leading Eight Monoclonal Antibody Therapeutics Markets, 2008
• Table 4.2 US, Canada, France, Germany, Spain, Italy, UK, Japan, China & India Monoclonal Antibody Market Forecasts, 2009-2024
• Table 4.3 US Monoclonal Antibody Sales by Therapeutic Area, 2008
• Table 4.4 Leading Ten US Monoclonal Antibodies, 2008
• Table 5.1 Oncology Pipeline: Additional Indications for Avastin
• Table 5.2 Oncology Pipeline: Additional Indications for Approved Drugs (Other than Avastin)
• Table 5.3 Oncology Pipeline: Selected New Entities in Phase III or Regulatory/Submission
• Table 5.4 Oncology Pipeline: Selected New Entities in Phase II, Part 1
• Table 5.5 Oncology Pipeline: Selected New Entities in Phase II, Part 2
• Table 5.6 Autoimmune Disorders Pipeline: Additional Indications for Approved Drugs
• Table 5.7 Autoimmune Disorder Pipeline: Selected New Entities in Phase III/Regulatory Submission: Part 1
• Table 5.8 Autoimmune Disorder Pipeline: Selected New Entities in Phase III/Regulatory Submission: Part 2
• Table 5.9 Autoimmune Disorder Pipeline: Selected New Entities in Phase II
• Table 5.10 Pipeline for Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders)
• Table 5.11 Antibody Fragment Pipeline
• Table 5.12 Antibody-Cytotoxic Drug Conjugate Pipeline: Part 1
• Table 5.13 Antibody-Cytotoxic Drug Conjugate Pipeline: Part 2
• Table 6.1 SWOT Chart for the Monoclonal Antibody Therapeutics Industry, 2009-2024
• Table 6.2 Monoclonal Antibody Targets
• Table 6.3 Expected Patent Expiries for Monoclonal Antibodies
• Table 6.4 Biosimilar Monoclonal Antibodies in Development

List of Figures

• Figure 2.1 Antibody Structure
• Figure 3.1 Monoclonal Antibody Therapeutic Area Market Share, 2008
• Figure 3.2 Leading Monoclonal Antibodies Market Share, 2008
• Figure 3.3 Monoclonal Antibody Technology Type Market Share, 2008
• Figure 3.4 Monoclonal Antibody Type Market Share, 2008
• Figure 3.5 Monoclonal Antibody Marketing Company Market Share, 2008
• Figure 3.6 Total Monoclonal Antibodies Sales Forecast, 2009-2024
• Figure 3.7 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2009-2024
• Figure 3.8 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Market Share, 2009-2024
• Figure 3.9 Leading Oncology Monoclonal Antibodies Market Share, 2008
• Figure 3.10 Technology Type Market Share, Oncology Monoclonal Antibodies, 2008
• Figure 3.11 Antibody Type Market Share, Oncology Monoclonal Antibodies, 2008
• Figure 3.12 Marketing Company Market Share, Oncology Monoclonal Antibodies, 2008
• Figure 3.13 Total Oncology Monoclonal Antibodies Sales Forecast, 2009-2024
• Figure 3.14 MabThera/Rituxan, Avastin, Herceptin and Erbitux & Other Oncology Monoclonal Antibodies Market Share, 2009-2024
• Figure 3.15 MabThera/Rituxan Marketing Company Market Share, 2008
• Figure 3.16 MabThera/Rituxan Country Market Share, 2008
• Figure 3.17 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2009-2024
• Figure 3.18 Avastin Marketing Company Market Share, 2008
• Figure 3.19 Avastin Country Market Share, 2008
• Figure 3.20 Avastin Sales Forecast, 2009-2024
• Figure 3.21 Herceptin Marketing Company Market Share, 2008
• Figure 3.22 Herceptin Country Market Share, 2008
• Figure 3.23 Herceptin Sales Forecast, 2009-2024
• Figure 3.24 Erbitux Marketing Company Market Share, 2008
• Figure 3.25 Erbitux Sales Country Market Share, 2008
• Figure 3.26 Erbitux Sales Forecast, 2009-2024
• Figure 3.27 Leading Autoimmune Disorder Monoclonal Antibodies Market Share, 2008
• Figure 3.28 Technology Type Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008
• Figure 3.29 Antibody Type Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008
• Figure 3.30 Marketing Company Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008
• Figure 3.31 Total Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2009-2024
• Figure 3.32 Remicade, Humira, Simponi, & Other Autoimmune Disorder Monoclonal Antibodies Market Share, 2009-2024
• Figure 3.33 Remicade Marketing Company Market Share, 2008
• Figure 3.34 Remicade Country Market Share, 2008
• Figure 3.35 Remicade Sales Forecast, 2009-2024
• Figure 3.36 Humira Marketing Company Market Share, 2008
• Figure 3.37 Humira Country Market Share, 2008
• Figure 3.38 Humira Sales Forecast, 2009-2024
• Figure 3.39 Cimzia Sales Forecast, 2009-2024
• Figure 3.40 Simponi Sales Forecast, 2009-2024
• Figure 3.41 Xolair Sales Forecast, 2009-2024
• Figure 3.42 Tysabri Country Market Share, 2008
• Figure 3.43 Tysabri Sales Forecast, 2009-2024
• Figure 3.44 Total Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2009-2024
• Figure 3.45 Lucentis Marketing Company Market Share, 2008
• Figure 3.46 Lucentis Country Market Share, 2008
• Figure 3.47 Lucentis Sales Forecast, 2009-2024
• Figure 3.48 Synagis Marketing Company Market Share, 2008
• Figure 3.49 Synagis Country Market Share, 2008
• Figure 3.50 Synagis/Motavizumab Sales Forecast, 2009-2024
• Figure 4.1 Leading Eight Monoclonal Antibody Therapeutics Markets, 2008
• Figure 4.2 US, Canada, France, Germany, Spain, Italy, UK, Japan, China & India Monoclonal Antibody Market Forecasts, 2009-2024
• Figure 4.3 US Monoclonal Antibody Sales by Therapeutic Area, 2008
• Figure 4.4 Leading Ten US Monoclonal Antibodies, 2008
• Figure 4.5 US Monoclonal Antibodies Sales Forecast, 2009-2024
• Figure 5.1 Antibody Fragment Types
• Figure 8.1 World Monoclonal Antibody Therapeutics Market Forecast, 2009-2024

• Abbott
• Abgenix (acquired by Amgen, 2006)
• Ablynx
• Actinium
• Affimed Therapeutics
• Alcon (Nestle)
• Alexion
• Amgen
• Arana Therapeutics
• AstraZeneca
• Bayer
• Biocon
• Biogen (merged with IDEC in 2003 to form Biogen Idec)
• Biogen Idec
• BioTech Pharma [Chinese/Cuban joint venture]
• Biotest
• Boehringer Ingelheim
• Bradmer
• Bristol-Myers Squibb
• Cambridge Antibody Technology (CAT) (acquired by AstraZeneca)
• Cell Therapeutics
• Celltech (acquired by UCB, 2004)
• Center of Molecular Immunology [Cuba]
• Centocor (acquired by Johnson & Johnson, 1999)
• Cephalon
• Ception Therapeutics
• Chugai (majority-owned by Roche)
• Committee for Medicinal Products for Human Use (CHMP) (part of EMEA)
• Corixa (acquired by GSK, 2005)
• Daiichi-Sankyo
• Dainippon Sumitomo
• Domantis (acquired by GSK, 2007)
• Dr. Reddy' s Laboratories
• Eisai
• Elan
• Eli Lilly
• ESBATech
• Esteve
• Eurofarma [Brazil]
• European Medicines Agency (EMEA)
• Facet Biotech (formerly part of PDL BioPharma)
• Food and Drug Administration (FDA) [US]
• Fresenius
• Genentech (acquired by Roche in March 2009)
• Genmab
• Genzyme
• GSK (GlaxoSmithKline)
• GTC Biotherapeutics
• Health Canada
• Human Genome Sciences
• IDEC (merged with Biogen in 2003 to form Biogen Idec)
• Ilex Oncology (acquired by Genzyme, 2004)
• ImClone (acquired by Eli Lilly, November 2008)
• ImmunoGen
• Immunomedics
• Implicit Bioscience
• Johnson & Johnson
• Kyowa Hakko Kirin
• Laboratorio Elea [Argentina]
• LFB Biotechnologies
• Ludwig Institute for Cancer Research
• MacroGenics
• Medarex
• MedImmune (acquired by AstraZeneca, 2007)
• Menarini
• Merck & Co.
• Merck KGaA
• Micromet
• Millennium (acquired by Takeda, 2008)
• Ministry of Health, Labour and Welfare (MHLW) [Japan]
• Mitsubishi Tanabe
• Morphotek (acquired by Eisai, 2007)
• National Cancer Institute (NCI, part of NIH) [US]
• National Eye Institute (NEI, part of NIH) [US]
• National Institutes of Health (NIH) [US]
• NeuTec (acquired by Novartis, 2006)
• Novartis
• Nycomed
• Oncoscience
• Onyx
• Osaka University
• Otsuka
• PDL BioPharma
• Peregrine
• Pfizer
• Pierre Fabre
• Progenics
• Ranbaxy
• Rinat (acquired by Pfizer, 2006)
• Roche
• Roche Group (Roche, Genentech & Chugai)
• Sanofi-Aventis
• Schering-Plough
• Seattle Genetics
• Shanghai Medipharm Biotech (Medipharm)
• Shantha Biotechnics
• Spectrum
• State Food and Drug Administration (SFDA) [China]
• Takeda
• Tanox (acquired by Genentech in 2007
• Tolerx
• Trion
• UCB
• University of Massachusetts Medical School
• Viventia
• Wilex
• Wyeth
• Xoma
• YM Biosciences
• Zenotech
• Zenyaku Kogyo